NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.42B
This Quarter Return
+24.42%
1 Year Return
+12.08%
3 Year Return
+99.82%
5 Year Return
+98.46%
10 Year Return
+612.59%
AUM
$1.26B
AUM Growth
+$1.26B
(+27%)
Cap. Flow
+$32.9M
Cap. Flow
% of AUM
2.61%
Top 10 Holdings %
Top 10 Hldgs %
89.49%
Holding
23
New
5
Increased
5
Reduced
4
Closed
–
Top Buys
| 1 |
ETTX
Entasis Therapeutics Holdings Inc.
ETTX
|
$23.7M |
| 2 |
AERI
Aerie Pharmaceuticals, Inc.
AERI
|
$17.4M |
| 3 |
Neuronetics
STIM
|
$16.8M |
| 4 |
Galapagos
GLPG
|
$9.84M |
| 5 |
Amicus Therapeutics
FOLD
|
$6.85M |
Top Sells
| 1 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$26M |
| 2 |
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
|
$22.4M |
| 3 |
Merus
MRUS
|
$6.07M |
| 4 |
IVTY
Invuity, Inc
IVTY
|
$1.14M |
Sector Composition
| 1 | Healthcare | 94.03% |
| 2 | Financials | 0.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Inogen
INGN
$216M
| $866M | 68.79% | 3,549,320 | – | – |
|
2
Glaukos
GKOS
$5.5B
| $39.1M | 3.11% | 602,709 | – | – |
|
3
Corvus Pharmaceuticals
CRVS
$428M
| $37.9M | 3.01% | 4,420,516 | – | – |
|
|
XLRN
4
DELISTED
Acceleron Pharma Inc.
XLRN
| $37.2M | 2.95% | 650,000 -453,937 | -41% | -$26M |
|
5
Akebia Therapeutics
AKBA
$833M
| $27.4M | 2.17% | 3,100,000 | – | – |
|
|
AERI
6
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $25.1M | 2% | 408,562 +282,165 | +223% | +$17.4M |
|
|
DERM
7
DELISTED
Dermira, Inc.
DERM
| $24.5M | 1.95% | 1,993,746 | – | – |
|
8
OrthoPediatrics
KIDS
$536M
| $24M | 1.9% | 654,549 +1,200 | +0.2% | +$44K |
|
|
ETTX
9
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
| $23.7M | 1.88% | +2,181,843 | New | +$23.7M |
|
|
10
Merus
MRUS
$4.98B
| $21.8M | 1.73% | 1,102,795 -307,622 | -22% | -$6.07M |
|
|
11
Amicus Therapeutics
FOLD
$2.34B
| $19.9M | 1.58% | 1,647,870 +566,689 | +52% | +$6.85M |
|
|
12
Neuronetics
STIM
$220M
| $16.8M | 1.34% | +525,000 | New | +$16.8M |
|
|
SPNE
13
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $15.3M | 1.21% | 983,037 +55,249 | +6% | +$860K |
|
14
VYNE Therapeutics
VYNE
$8.16M
| $14.1M | 1.12% | 1,436,313 | – | – |
|
|
NBRV
15
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| $12.7M | 1.01% | 4,703,720 +1,815,000 | +63% | +$4.9M |
|
|
16
Galapagos
GLPG
$2.07B
| $9.84M | 0.78% | +87,481 | New | +$9.84M |
|
|
VRNA
17
Verona Pharma
VRNA
$9.16B
| $9.27M | 0.74% | 740,740 | – | – |
|
|
IVTY
18
DELISTED
Invuity, Inc
IVTY
| $8.95M | 0.71% | 1,209,854 -153,994 | -11% | -$1.14M |
|
19
Cogent Biosciences
COGT
$1.69B
| $6.85M | 0.54% | 665,181 | – | – |
|
|
WMGIZ
20
DELISTED
Wright Medical Group, Inc. Contingent Value Right
WMGIZ
| – | – | 0 | – | – |
|
21
Crinetics Pharmaceuticals
CRNX
$2.92B
| $4.3M | 0.34% | +150,000 | New | +$4.3M |
|
|
RARX
22
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $4.07M | 0.32% | 225,000 -1,240,838 | -85% | -$22.4M |
|
23
Citigroup
C
$178B
| $3.77M | 0.3% | +52,500 | New | +$3.77M |
|